Rhea-AI Summary
AngioSoma Inc. (SOAN) announced an amendment to their Exclusive Global Multiple Sclerosis License Agreement on February 4, 2021, enhancing their collaboration with the licensee to market and license Patent 10,619,592. CEO Alexanderia Blankenship expressed optimism about upcoming trials and potential commercialization if outcomes are favorable. The company, through its subsidiary SomaCeuticals, focuses on innovative wellness products and aims to expand market offerings. This strategic move aligns with the company’s goals for growth in the wellness sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags